CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16PRNewsWire • 06/09/21
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 06/02/21
CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow CancerBenzinga • 06/01/21
CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with MyelofibrosisPRNewsWire • 06/01/21
CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14PRNewsWire • 04/07/21
CTI BioPharma Corp. Announces Pricing of its Public Offering of Common Stock and Preferred StockPRNewsWire • 04/01/21
CTI BioPharma Corp. Announces Proposed Public Offering of Common Stock and Preferred StockPRNewsWire • 03/31/21
CTI BioPharma Stock Is Trading Higher On Complete Submission For Rolling Pacritinib US ApplicationBenzinga • 03/31/21
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe ThrombocytopeniaPRNewsWire • 03/31/21
CTI BioPharma's Pacritinib Demonstrates Positive Safety Profile In Graft-Versus-Host-Disease StudyBenzinga • 03/22/21
Phase 1 Trial Demonstrates Encouraging Clinical Benefit and Promising Safety Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer ResearchPRNewsWire • 03/22/21
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/17/21
CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021PRNewsWire • 03/12/21
CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, Dec. 15PRNewsWire • 12/08/20